Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Ciputra Development Tbk, (CTRA) Fair Value & Analysis

Real Estate · ID · Market cap 10.2T IDR

Price545.00 IDR
Fair Value1,363 IDR
Upside+150.0%
Quality86/100
Evidence: Medium Range 1,006 IDR – 1,767 IDR

Analysis

PT Ciputra Development Tbk, (CTRA) currently trades at 545.00 IDR, while our model-based Fair Value estimate is 1,363 IDR — implying the stock looks roughly 150.0% undervalued today. We read business quality at 86/100 (high quality), in the Real Estate sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

PT Ciputra Development Tbk, together with its subsidiaries, develops and sells real estate properties in Indonesia. The company operates through Real Estate and Rental segments. It develops, sells, and maintains houses, shophouses, warehouses, apartments, office towers, malls, hotels, golf courses, waterparks, and hospitals and healthcare facilities. The company was formerly known as PT Citra Habitat Indonesia and changed its name to PT Ciputra Development Tbk in December 1990. PT Ciputra Development Tbk was founded in 1981 and is based in Jakarta, Indonesia. PT Ciputra Development Tbk operates as a subsidiary of PT Sang Pelopor.

Open the full interactive analysis →

Similar stocks

Dar Global PLC (DAR) -88% Vinhomes Joint Stock Company (VHM) +150% DLF Limited (DLF) -66% PT Pantai Indah Kapuk Dua Tbk, (PANI) -80% Lodha Developers Limited (LODHA) -19% Oberoi Realty Limited (OBEROIRLTY) -1%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.